In patients with moderate-to-severe psoriasis treated with systemic therapies, including adalimumab, etanercept, infliximab, and ixekizumab, studies have reported reductions in erythrocyte sedimentation rate (ESR) and/or CRP levels [149,150,151,152]. Here, CRP is linked to psoriasis.